L
Laura Michel
Researcher at University Hospital Heidelberg
Publications - 25
Citations - 253
Laura Michel is an academic researcher from University Hospital Heidelberg. The author has contributed to research in topics: Breast cancer & Medicine. The author has an hindex of 4, co-authored 10 publications receiving 38 citations. Previous affiliations of Laura Michel include Heidelberg University & German Cancer Research Center.
Papers
More filters
Journal ArticleDOI
Clinical and molecular characteristics of HER2-low-positive breast cancer: pooled analysis of individual patient data from four prospective, neoadjuvant clinical trials.
Carsten Denkert,Fenja Seither,Andreas Schneeweiss,Theresa Link,Jens-Uwe Blohmer,Marianne Just,Pauline Wimberger,A Forberger,Hans Tesch,Christian Jackisch,Sabine Schmatloch,Mattea Reinisch,Erich Solomayer,Wolfgang D. Schmitt,Claus Hanusch,Peter A. Fasching,Kristina Lübbe,Christine Solbach,Jens Huober,Kerstin Rhiem,Frederik Marmé,Toralf Reimer,Marcus Schmidt,Bruno Valentin Sinn,Wolfgang Janni,Elmar Stickeler,Laura Michel,Oliver Stötzer,Eric Hahnen,Jenny Furlanetto,Sabine Seiler,Valentina Nekljudova,Michael Untch,Sibylle Loibl +33 more
TL;DR: In this article, the authors compared the clinical and molecular characteristics of HER2-low-positive and HER2zero breast cancer, including response to neoadjuvant chemotherapy and prognosis.
Journal ArticleDOI
Identification and characterization of cancer cells that initiate metastases to the brain and other organs
Anna S. Berghoff,Anna S. Berghoff,Anna S. Berghoff,Yunxiang Liao,Yunxiang Liao,Matthia A. Karreman,Matthia A. Karreman,Ayseguel Ilhan-Mutlu,Katharina Gunkel,Katharina Gunkel,Martin R. Sprick,Christian Eisen,Tobias Kessler,Tobias Kessler,Matthias Osswald,Matthias Osswald,Susanne Wünsche,Susanne Wünsche,Manuel Feinauer,Manuel Feinauer,Brunhilde Gril,Frederic Marmé,Laura Michel,Zuszanna Bago-Horvath,Felix Sahm,Felix Sahm,Natalia Becker,Michael O. Breckwoldt,Gergely Solecki,Gergely Solecki,Miriam Gömmel,Miriam Gömmel,Lulu Huang,Lulu Huang,Petra Rübmann,Carina M. Thome,Miriam Ratliff,Miriam Ratliff,Andreas Trumpp,P. S. Steeg,Matthias Preusser,Wolfgang Wick,Wolfgang Wick,Frank Winkler,Frank Winkler +44 more
TL;DR: The data identify temporary slow-cycling breast cancer cells as the dominant source of brain and other metastases and demonstrates that this can lead to better understanding of BMIC-relevant pathways, including potential new approaches to prevent BM in patients.
Journal ArticleDOI
Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases.
Anna S. Berghoff,Anna S. Berghoff,Michael O. Breckwoldt,Lars Riedemann,Lars Riedemann,Kianush Karimian-Jazi,Sarah Loew,Sarah Loew,Franziska Schlieter,Julia Furtner,Marc Cinci,Michael Thomas,Moritz J. Strowitzki,Frederik Marmé,Laura Michel,Thomas Schmidt,Dirk Jäger,Martin Bendszus,Matthias Preusser,Wolfgang Wick,Wolfgang Wick,Frank Winkler,Frank Winkler +22 more
TL;DR: Bvacizumab-based treatment had clinically relevant intracranial activity in the vast majority of patients suffering from recurrent, symptomatic BM and supports a prospective clinical trial of bevacIZumab as a salvage treatment in BM.
Journal ArticleDOI
Implementation of CDK4/6 Inhibitors and its Influence on the Treatment Landscape of Advanced Breast Cancer Patients – Data from the Real-World Registry PRAEGNANT
T Engler,Peter A. Fasching,Diana Lüftner,Andreas D. Hartkopf,Volkmar Müller,Hans-Christian Kolberg,Peyman Hadji,Hans Tesch,Lothar Häberle,Johannes Ettl,Markus Wallwiener,Matthias W. Beckmann,Alexander Hein,Erik Belleville,Sabrina Uhrig,Pauline Wimberger,Carsten Hielscher,Christian M. Kurbacher,Rachel Wuerstlein,Michael Untch,Florin-Andrei Taran,Hans-Martin Enzinger,P Krabisch,Manfred Welslau,M. Maasberg,Dirk Hempel,Michael P. Lux,Laura Michel,Wolfgang Janni,Diethelm Wallwiener,Sara Y. Brucker,Tanja Fehm,Andreas Schneeweiss +32 more
TL;DR: A treatment with CDK4/6i + ET has rapidly become the therapy standard for patients in the first-line advanced breast cancer setting and recently mainly patients with a good prognosis are being treated with endocrine monotherapy, and patients who are treated with chemotherapy have an unfavorable prognosis.
Journal Article
T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice.
TL;DR: T-DM1 is effective and well-tolerated even in intensively pre-treated patients, and higher rates of newly-diagnosed cerebral metastasis and cerebral progression in patients with stable peripheral metastases are recorded compared to the EMILIA study.